We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Radiotherapy Better than Surgery for Some Lung Cancer Patients

By HospiMedica staff writers
Posted on 09 Apr 2007
After an initial chemotherapy treatment, radiation may be a better choice than surgery for patients with stage IIIA non-small-cell lung cancer, according to new research.

Findings from the randomized controlled trial were published in the March 21, 2007, issue of the [U.S.] Journal of the National Cancer Institute. More...
The researchers who performed the study suggest that a combination of chemotherapy and radiation should be the preferred treatment option for these patients.

About 80% of all lung cancers are non-small-cell lung cancers (NSCLCs), and of those patients diagnosed with NSCLC, approximately 30% have locally advanced stages IIIA or IIIB. Earlier research had shown that treating stage IIIA patients with chemotherapy before surgery increases the survival rate compared with patients receiving only surgery. The researchers had originally theorized that surgery would be more effective than radiation after chemotherapy treatment.

Jan van Meerbeeck, M.D., Ph.D., from the University Hospital of Ghent (Belgium) and colleagues from the European Organization for Research and Treatment of Cancer (EORTC) recruited 579 eligible patients from 41 institutions into the trial between December 1994 and December 2002. All of the patients were diagnosed with stage IIIA-N2 NSCLC that had progressed so far that it could not be completely removed by surgery.

The patients were first given three cycles of platinum-based chemotherapy. Those who responded to the treatment--61% of the initial group--were then randomly assigned to receive surgery or radiation, 167 and 165 patients, respectively.

The investigators discovered that surgery, compared to radiation, did not improve survival after treatment with chemotherapy. The median survival time for surgical patients was 16.4 months vs 17.5 months for patients who were treated with radiation. The five-year overall survival rate for surgical patients was 15.7%, compared with 14% for patients who received radiation. Although the survival rates for the two groups were very similar, the researchers concluded that radiation was the preferred treatment because of its lower rate of complications and mortality in lung cancer patients.

"These results are important because several centers routinely use…chemotherapy followed by surgery to treat patients with this stage of disease based on small randomized studies that showed that surgery alone is inferior to…chemotherapy and surgery in stage IIIA patients,” the authors wrote in their article.


Related Links:
University Hospital of Ghent

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Immobilization System
Cranial 4Pi Immobilization
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.